Beam Therapeutics (NASDAQ:BEAM) Stock Price Up 11.3% – Here’s Why

Beam Therapeutics Inc. (NASDAQ:BEAM)’s share price traded up 11.3% during trading on Wednesday. The stock traded as high as $27.92 and last traded at $27.7030. Approximately 2,530,090 shares changed hands during trading, an increase of 25% from the average session volume of 2,030,983 shares. The stock had previously closed at $24.90.

Beam Therapeutics News Summary

Here are the key news stories impacting Beam Therapeutics this week:

• Positive Sentiment: Pipeline progress supports the long-term story. Beam reviewed initial Phase 1/2 BEAM-301 data in glycogen storage disease type 1a, giving investors an additional clinical milestone to evaluate for the company’s base-editing platform. Beam Therapeutics Reviews Initial BEAM-301 Data
• Positive Sentiment: Analyst support remains a counterweight. Citi initiated coverage with a Buy rating, while a separate healthcare-stock roundup highlighted Beam among companies viewed favorably by analysts. HC Wainwright also maintained its Buy rating despite reducing several estimates. Beam Gets a Buy From Citi Analysts Are Bullish on Beam
• Neutral Sentiment: Recent momentum was substantial but may be difficult to sustain. BEAM rose 15.6% in the prior session on above-average volume, and its shares crossed above the 200-day moving average. However, commentary cautioned that recent earnings-estimate trends may not support another near-term advance. Beam Moves 15.6% Higher
• Negative Sentiment: Wedbush lowered its price target and downgraded the shares, creating the clearest immediate catalyst for the pullback after the rally. Beam Price Target Cut by Wedbush Beam Shares Cross 200-Day Moving Average
• Negative Sentiment: HC Wainwright trimmed most near- and long-term EPS forecasts. Estimates were reduced for 2026 through 2029, including FY2026 EPS to $(4.67) from $(4.64) and FY2027 EPS to $(5.23) from $(5.08). Although FY2030’s loss forecast improved, the revisions reinforce expectations for continued cash burn and losses. HC Wainwright Beam Earnings Estimates

Analyst Ratings Changes

Several equities research analysts have issued reports on BEAM shares. Wall Street Zen upgraded Beam Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, October 3rd. Canaccord Genuity Group lifted their price objective on Beam Therapeutics from $78.00 to $79.00 and gave the company a “buy” rating in a report on Thursday. Wedbush dropped their target price on shares of Beam Therapeutics from $65.00 to $28.00 and set an “outperform” rating on the stock in a report on Wednesday. William Blair raised shares of Beam Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 23rd. Finally, HC Wainwright reiterated a “buy” rating on shares of Beam Therapeutics in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Beam Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $46.90.

Beam Therapeutics Stock Performance

The stock has a fifty day moving average of $25.95 and a 200-day moving average of $28.22. The firm has a market capitalization of $2.81 billion, a P/E ratio of -31.66 and a beta of 2.20. The company has a quick ratio of 14.57, a current ratio of 14.57 and a debt-to-equity ratio of 0.09.

Beam Therapeutics (NASDAQ:BEAM) last released its earnings results on Tuesday, August 4th. The company reported ($1.18) EPS for the quarter, missing the consensus estimate of ($1.11) by ($0.07). The firm had revenue of $0.49 million during the quarter, compared to the consensus estimate of $16.37 million. Beam Therapeutics had a negative net margin of 54.75% and a negative return on equity of 30.71%. The company’s revenue was down 94.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.00) EPS. On average, research analysts anticipate that Beam Therapeutics Inc. will post -4.49 EPS for the current year.

Insiders Place Their Bets

In related news, CEO John Evans sold 25,000 shares of the firm’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $23.57, for a total value of $589,250.00. Following the completion of the transaction, the chief executive officer owned 1,047,205 shares of the company’s stock, valued at approximately $24,682,621.85. This trade represents a 2.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 3.80% of the company’s stock.

Institutional Investors Weigh In On Beam Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new position in shares of Beam Therapeutics in the 2nd quarter valued at about $308,796,000. ARCH Venture Management LLC bought a new stake in shares of Beam Therapeutics in the 2nd quarter valued at about $155,771,929. ADAR1 Capital Management LLC bought a new stake in Beam Therapeutics in the first quarter valued at approximately $34,467,000. Bank of America Corp DE bought a new position in shares of Beam Therapeutics during the 2nd quarter worth approximately $24,733,000. Finally, Elmind Capital LP bought a new position in shares of Beam Therapeutics during the 2nd quarter worth approximately $16,347,920. 99.68% of the stock is owned by institutional investors.

Beam Therapeutics Company Profile

Beam Therapeutics Inc is a biotechnology company developing precision genetic medicines for patients with serious diseases. The company’s platform uses base editing, a form of gene editing designed to make targeted changes to individual DNA letters without creating double-strand breaks. Beam is also advancing related editing technologies and delivery systems intended to improve the precision and effectiveness of genetic treatments.

Beam’s pipeline includes investigational programs for diseases such as sickle cell disease, beta thalassemia, alpha-1 antitrypsin deficiency and glycogen storage disease type Ia.